ETadmin, Author at Elevar Therapeutics

LSKB Announces its Clinical Initiative to Study the Safety and Efficacy of Combining Apatinib with Immunotherapy

December 10, 2017

SALT LAKE CITY, USA, December 10, 2017 -- LSK BioPharma (LSKB, Company) announced a new initiative to study the safety and efficacy of cancer therapies combining apatinib with immunotherapy. The first clinical study, designated LSK-AM107, will take place at the

LSKB is hiring a Senior Clinical Research Associate

November 29, 2017

Responsibilities and Duties Essential Duties & Responsibilities: Assist protocol, IB and CRF development Provide monitoring guidance Plan and assist study start-up activities such as the creation of Site Initiation Presentations, CRF Completion Guidelines and various study tracking and management documents Perform

LSKB is hiring a Global Clinical Project Manager

September 8, 2017

Position Summary: This position functions as a Clinical Project Manager for global late stage clinical trials within LSK BioPharma (South San Francisco) or within LSK Global CRO (Seoul) as the relevant study/project requires. The Global Clinical Trials Manager (GCTM) works

The US FDA grants Apatinib Orphan Drug Designation for Treatment of Gastric Cancer

June 19, 2017

SALT LAKE CITY, USA, June 19 2017 -- LSK BioPharma (LSKB, Company) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to apatinib for the treatment of gastric cancer. Apatinib, which has been approved and is marketed

LSK BioPharma to Attend and Present at the ASCO 2017 Annual Meeting

June 1, 2017

SALT LAKE CITY, USA, June 1 2017 -- LSK Biopharma (LSKB Company) will be attending the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA from June 2-6. The Company will be meeting with leading oncologists and key

LSK BioPharma Announces Starting of Site Initiation Visits in the U.S. for its Phase 3 Gastric Cancer Trial Studying Apatinib

May 16, 2017

SALT LAKE CITY, USA, May 16, 2017 – LSK BioPharma (LSKB, Company) announced today that it has started Site Initiation Visits (SIVs) for clinical sites in the United States for its global apatinib phase 3 gastric cancer trial. The Company

LSK BioPharma Announces Approval to Initiate a Phase 2 Clinical Trial in Colorectal Cancer in South Korea

May 8, 2017

SALT LAKE CITY, USA, May 8, 2017 – LSK BioPharma (LSKB, Company) announced today that it has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to initiate a phase 2 clinical trial of apatinib, the Company’s

LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer

March 13, 2017

SALT LAKE CITY, USA, March 13, 2017 – LSK BioPharma (LSKB, Company) announced today enrollment of the first patient in a global, multicenter phase 3 trial to evaluate apatinib in patients with advanced or metastatic gastric cancer. This first patient was

LSK BioPharma’s Apatinib Receives Orphan Drug Designation in the European Union

March 1, 2017

SALT LAKE CITY, USA, March 1, 2017 – LSK BioPharma (LSKB, Company) today announced that it has received notification that the European Commission has designated apatinib as an orphan medicinal product for the treatment of gastric cancer in the European

LSK BIOPHARMA RECEIVES APPROVAL TO INITIATE PHASE 3 FROM KOREA’S MFDS, EXPECTS FIRST-PATIENT-ENROLLED IN GLOBAL PHASE 3 SHORTLY

January 6, 2017

SALT LAKE CITY, January 6, 2017 – LSK BioPharma (LSKB) today announced that it received approval for its apatinib phase 3 protocol under the Korean Ministry of Food and Drug Safety (MFDS). South Korea will be a part of the

Author: ETadmin